Trial Profile
Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary) ; Vinorelbine (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 12 Dec 2023 Results evaluating clinical responses to Pembrolizumab + GVD in Patients with Relapsed Hodgkin Lymphoma,presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 01 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 01 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.